中华老年多器官疾病杂志
中華老年多器官疾病雜誌
중화노년다기관질병잡지
CHINESE JOURNAL OF MULTIPLE ORGAN DISEASES IN THE ELDERLY
2014年
2期
116-118
,共3页
利奈唑胺%血红蛋白类%血小板%出血%老年人
利奈唑胺%血紅蛋白類%血小闆%齣血%老年人
리내서알%혈홍단백류%혈소판%출혈%노년인
linezolid%hemoglobins%blood platelets%hemorrhage%aged
目的:观察利奈唑胺对耐甲氧西林金黄色葡萄球菌(MRSA)感染的高龄男性患者血液生理指标及安全性的影响。方法选取2012年4月至2013年3月在解放军总医院住院并确诊MRSA感染的46例高龄男性患者(83~95岁),均给予利奈唑胺注射液治疗,0.6g、1次/12h,疗程10~14d。比较治疗前后红细胞(RBC)、血红蛋白(HB)、白细胞(WBC)、血小板(PLT)和网织红细胞(Ret)等血液生理指标变化。观察治疗期间出血不良反应。结果治疗后与治疗前比较,HB[(95.609±14.210) vs (102.478±15.941)g/L]、WBC×1012/L [(6.944±2.590) vs (8.728±2.277)]、Ret[(1.124%±0.844%) vs (1.789%±0.831%)]和PLT×109/L [(142.913±62.065) vs (227.304±56.250)]均显著降低,差异均有统计学意义(P<0.01)。治疗期间共有22例患者发生出血倾向,出现2个部位出血患者10例(22%),3个部位出血患者4例(9%),≥4个部位出血患者2例。结论利奈唑胺能降低高龄男性患者HB、PLT、Ret水平,治疗期间需警惕出血并发症。
目的:觀察利奈唑胺對耐甲氧西林金黃色葡萄毬菌(MRSA)感染的高齡男性患者血液生理指標及安全性的影響。方法選取2012年4月至2013年3月在解放軍總醫院住院併確診MRSA感染的46例高齡男性患者(83~95歲),均給予利奈唑胺註射液治療,0.6g、1次/12h,療程10~14d。比較治療前後紅細胞(RBC)、血紅蛋白(HB)、白細胞(WBC)、血小闆(PLT)和網織紅細胞(Ret)等血液生理指標變化。觀察治療期間齣血不良反應。結果治療後與治療前比較,HB[(95.609±14.210) vs (102.478±15.941)g/L]、WBC×1012/L [(6.944±2.590) vs (8.728±2.277)]、Ret[(1.124%±0.844%) vs (1.789%±0.831%)]和PLT×109/L [(142.913±62.065) vs (227.304±56.250)]均顯著降低,差異均有統計學意義(P<0.01)。治療期間共有22例患者髮生齣血傾嚮,齣現2箇部位齣血患者10例(22%),3箇部位齣血患者4例(9%),≥4箇部位齣血患者2例。結論利奈唑胺能降低高齡男性患者HB、PLT、Ret水平,治療期間需警惕齣血併髮癥。
목적:관찰리내서알대내갑양서림금황색포도구균(MRSA)감염적고령남성환자혈액생리지표급안전성적영향。방법선취2012년4월지2013년3월재해방군총의원주원병학진MRSA감염적46례고령남성환자(83~95세),균급여리내서알주사액치료,0.6g、1차/12h,료정10~14d。비교치료전후홍세포(RBC)、혈홍단백(HB)、백세포(WBC)、혈소판(PLT)화망직홍세포(Ret)등혈액생리지표변화。관찰치료기간출혈불량반응。결과치료후여치료전비교,HB[(95.609±14.210) vs (102.478±15.941)g/L]、WBC×1012/L [(6.944±2.590) vs (8.728±2.277)]、Ret[(1.124%±0.844%) vs (1.789%±0.831%)]화PLT×109/L [(142.913±62.065) vs (227.304±56.250)]균현저강저,차이균유통계학의의(P<0.01)。치료기간공유22례환자발생출혈경향,출현2개부위출혈환자10례(22%),3개부위출혈환자4례(9%),≥4개부위출혈환자2례。결론리내서알능강저고령남성환자HB、PLT、Ret수평,치료기간수경척출혈병발증。
Objective To determine the effects of linezolid on the routine blood indices and investigate the safety in the very old male patients with meticillin-resistant Staphylococcus aureus (MRSA) infection. Methods A total of 46 male patients (aged 83-95 years) with confirmed MRSA infection in Chinese PLA General Hospital from April 2012 to March 2013 were enrolled in this study. They were all treated with intravenous injection of 0.6g linezolid, once every 12h, for 10 to 14d. Their routine blood indices such as red blood cell (RBC), hemoglobin (HB), white blood cell (WBC), platelet (PLT) and reticulocyte (Ret) were compared before and after the treatment. The hemorrhage events were recorded during the treatment. Results After treatment with linezolid, the level of HB [(95.609±14.210) vs (102.478±15.941)g/L], count of WBC[×1012/L, (6.944±2.590) vs (8.728±2.277)], Ret [(1.124%±0.844%) vs (1.789%±0.831%)] and PLT[×109/L, (142.913±62.065) vs (227.304±56.250)] were significantly decreased compared with before treatment (P<0.01). Bleeding events occurred in 22 patients. Among them, 10 patients (22%) had 2 bleeding sites, 4 patients (9%) had 3 bleeding sites, 2 patients had ≥4 bleeding sites. Conclusion Linezolid decreases the serum levels of PLT, HB and Ret in very old male patients with MRSA. So a special attention should be paid to bleeding during the treatment.